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Introduction {#ehf212457-sec-0004}
============

Percutaneous mitral valve repair (PMVR) with MitraClip has proven to effectively reduce mitral regurgitation (MR) and improve symptoms in patients at high risk for conventional surgery.[1](#ehf212457-bib-0001){ref-type="ref"} Cardiopulmonary exercise test (CPET) is a valuable key tool to evaluate functional capacity, determine prognosis, and guide therapies in patients with heart failure with reduced ejection fraction (HFrEF).[2](#ehf212457-bib-0002){ref-type="ref"}, [3](#ehf212457-bib-0003){ref-type="ref"} To the best of our knowledge, no data are available regarding changes in CPET after PMVR.

Aim {#ehf212457-sec-0005}
===

Our aim was to evaluate changes in CPET after PMVR in patients with HFrEF who are potentially candidates for heart transplantation or destination left ventricular assist device.

Methods {#ehf212457-sec-0006}
=======

We conducted a prospective registry of all consecutive patients with functional MR (FMR) and HFrEF who underwent elective PMVR between October 2015 and March 2018 in our institution. Patients with preserved or mid‐range left ventricular ejection fraction (LVEF \> 40%), advanced age (\>75 years old), or severe co‐morbidities (end‐stage organ damage) were not included. Patients with unimpaired pre‐procedural VO~2~ \> 18 mL/kg/min were excluded (*Figure* [*1*](#ehf212457-fig-0001){ref-type="fig"}). All patients underwent invasive angiogram before PMVR to exclude significant coronary artery disease, with two patients being revascularized within prior 90 days before clip implantation. Treadmill exercise testing with respiratory gas exchange analysis was carried out in 11 patients within the month prior to the procedure and at 6 month follow‐up using a Schiller MTM‐1500 ergometer (Polymed Chirurgical, Montreal, Canada). Current recommendations for CPET in this scenario were followed.[4](#ehf212457-bib-0004){ref-type="ref"} Wasserman\'s equation was used to estimate predicted VO~2~ in each subject according to sex, predicted weight, and the use of treadmill test.[5](#ehf212457-bib-0005){ref-type="ref"} Patients breathed exclusively through a face mask and exhaled gases were analysed using sensors that allow breath‐by‐breath analysis with real‐time plotting of the mean values. Respiratory exchange ratio (RER), defined as the ratio between carbon dioxide output and oxygen uptake, was estimated as a 10 to 60 s averaged value depending on the exercise protocol. A cut‐off point ≥1.05 was set as an optimal exercise effort for maximal oxygen consumption (VO~2~) estimation. In case of a RER between 1 and 1.05, the exercise was considered sufficient for peak VO~2~ calculation if fulfilling one of the following criteria: achievement ventilatory anaerobic threshold, plateau in the VO~2~, maximal heart rate ≥90%, or perceived exertion with the Borg scale ≥8. CPETs with a RER below 1 were excluded. Clinical, echocardiographic, and laboratory features were also collected.

![Inclusion and exclusion criteria: flow chart for selection of patients. FMR, functional mitral regurgitation; GFR, glomerular filtrate rate; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; OMT, optimal medical therapy; PMVR, percutaneous mitral valve repair; VO~2~, maximal peak oxygen consumption.](EHF2-6-867-g001){#ehf212457-fig-0001}

Continuous variables were summarized as medians and interquartile range and compared using paired non‐parametric Wilcoxon sign rank sum tests. Categorical variables were described as percentages and compared using paired McNemar test. A *P*‐value of \<0.05 was considered statistically significant.

Results {#ehf212457-sec-0007}
=======

Baseline characteristics of included cohort are shown in *Table* [1](#ehf212457-tbl-0001){ref-type="table"}. All patients were at optimal medical therapy at maximum dose tolerated according to heart failure (HF) guidelines before PMVR: 100% were on beta‐blockers, and all but two patients with severe chronic kidney disease were on inhibitors of the renin--angiotensin system. No significant changes in medical therapy were observed at 6 month follow‐up (*Table* [2](#ehf212457-tbl-0002){ref-type="table"}). PMVR was successfully performed in all patients. At 6 month follow‐up, PMVR was associated with an improvement in New York Heart Association functional class and LVEF and a reduction in MR severity and N‐terminal pro‐brain natriuretic peptide (*Table* [2](#ehf212457-tbl-0002){ref-type="table"}). All patients completed pre‐procedural and post‐procedural CPET, and all the studies showed a RER ≥ 1 and were consistent with sufficient exercise effort. Compared with pre‐procedural CPET, patients showed a significant increase in exercise time (*P* = 0.047), VO~2~ (*P* = 0.033), ventilatory anaerobic threshold (*P* = 0.033), peak O~2~ pulse (*P* = 0.033), and workload (*P* = 0.049) (*Table* [2](#ehf212457-tbl-0002){ref-type="table"} and *Figures* [2](#ehf212457-fig-0002){ref-type="fig"}, [3](#ehf212457-fig-0003){ref-type="fig"}, [4](#ehf212457-fig-0004){ref-type="fig"}).

###### 

Baseline characteristics of patiets included in the study

  Age (years)   Sex      BMI (kg/m^2^)   DM    DCM             Prior coronary revascularization   Cardiac implantable device   AF           COPD   CKD   SHFM (%)   HFSS (%)   MAGGIC HF risk score (%)   Pre‐PMVR HF Admissions (12 months)   MR   LVEF (%)   GLS (%)   NYHA functional class   VO~2~ before (mL/kg/min)   VO~2~ after (mL/kg/min)
  ------------- -------- --------------- ----- --------------- ---------------------------------- ---------------------------- ------------ ------ ----- ---------- ---------- -------------------------- ------------------------------------ ---- ---------- --------- ----------------------- -------------------------- -------------------------
  67            Female   22.4            No    Non‐ischaemic   ---                                ICD                          Permanent    No     No    93.2       Low        9.3                        0                                    4+   20         −6.0      2                       13.4                       7.7
  71            Female   22.9            No    Non‐ischaemic   ---                                ICD                          No           No     Yes   92.6       Low        8.4                        1                                    4+   30         −6.0      2                       9.8                        15.8
  72            Male     31.1            No    Non‐ischaemic   ---                                No                           Permanent    No     Yes   91.9       Low        9.3                        1                                    4+   35         −6.1      3                       6.7                        13.3
  55            Male     25.9            No    Ischaemic       PCI                                No                           No           No     Yes   78.7       Low        8.4                        2                                    4+   38         −11.6     3                       18.0                       23.5
  55            Male     23.6            No    Ischaemic       PCI                                ICD                          Paroxysmal   No     No    95.7       Low        5.2                        3                                    4+   35         −10.2     2                       16.3                       29.1
  73            Male     24.9            Yes   Ischaemic       PCI                                No                           No           Yes    No    86.3       High       22.7                       1                                    4+   27         −9.5      3                       7.6                        13.5
  73            Male     25.2            No    Non‐ischaemic   ---                                ICD                          Paroxysmal   No     No    91.0       Medium     20.9                       2                                    4+   25         −4.7      3                       9.5                        16.8
  67            Male     24.9            Yes   Ischaemic       CABG                               No                           Permanent    No     Yes   70.3       Medium     22.7                       2                                    4+   35         −8.7      3                       9.2                        12.1
  59            Male     27.2            No    Ischaemic       PCI                                ICD                          Paroxysmal   No     No    87.9       Medium     11.1                       2                                    3+   25         −6,6      3                       9.1                        13.9
  69            Female   34.9            Yes   Non‐ischaemic   ---                                No                           No           No     No    93.2       Low        9.3                        0                                    4+   33         −14.8     3                       12.2                       8.6
  63            Male     25.2            Yes   Non‐ischaemic   ---                                ICD/CRT                      Paroxysmal   No     Yes   79.3       Low        19.1                       4                                    4+   25         −7.2      3                       11.9                       13.4

AF, atrial fibrillation; BMI, body mass index; CABG, coronary artery bypass grafting; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; CRT, cardiac resynchronization therapy; DM, diabetes mellitus; DCM, dilated cardiomyopathy; GLS, global longitudinal strain; HF, heart failure; HFSS, Heart Failure Survival Score; ICD, implantable cardioverter defibrillator; LVEF, left ventricular ejection fraction; MR, mitral regurgitation; NYHA, New York Heart Association; PCI, percutaneous coronary intervention; PMVR, percutaneous mitral valve repair; SHFM, Seattle Heart Failure Model.

###### 

Changes in cardiopulmonary exercise test and clinical, echocardiographic, and biochemical follow‐up

                                                     Pre‐procedural          Post‐procedural       P‐value
  ---------------------------------------------- ----------------------- ------------------------ ---------
  Reason for stopping                                     90.9                     72.7              NS
  Exhaustion/dyspnoea                                      9.1                     18.2           
  Claudication                                              0                      9.1            
  Time (s)                                          295 \[110--335\]         405 \[261--540\]       0.047
  Peak heart rate (b.p.m.)                          130 \[110--153\]         130 \[115--141\]        NS
  Peak SBP (mmHg)                                   140 \[120--150\]         140 \[110--150\]        NS
  Double product                                  17980 \[13200--2950\]   16100 \[13300--21150\]     NS
  VO~2~ (mL/kg/min)                                 9.8 \[9.1--13.4\]      13.5 \[12.1--16.8\]      0.033
  VO~2~/predicted VO~2~ (%)                        39.2 \[30.3--6.3\]      52.6 \[44.2--68.8\]      0.033
  VAT (mL/kg/min)                                   510 \[430--950\]        850 \[670--1070\]       0.033
  RER                                              1.18 \[1.13--1.24\]     1.16 \[1.07--1.29\]       NS
  VE/VO~2~ slope                                   30.0 \[27.0--38.6\]     31.5 \[23.7--39.7\]       NS
  Peak O~2~ pulse (mL/beat)                         7.2 \[4.3--8.6\]        8.3 \[6.2--11.8\]       0.013
  OUES                                             1035 \[754--1657\]       1135 \[997--2324\]      0.033
  Workload (METs)                                      5 \[3--6\]               6 \[5--8\]          0.049
  NYHA (%)                                                                                          0.021
  1                                                         0                      36.4           
  2                                                       27.3                     54.6           
  3                                                       72.7                     9.1            
  4                                                         0                       0             
  MR (%)                                                                                            0.013
  1+                                                        0                      36.4           
  2+                                                        0                      45.5           
  3+                                                       9.1                     9.1            
  4+                                                      90.9                     9.1            
  LVEF (%)                                            33 \[25--35\]           35 \[29--45\]         0.040
  NT‐proBNP (pg/mL)                                2805 \[1878--5022\]      1485 \[654--3032\]      0.012
  Beta‐blockers (%)                                        100                     90.9              NS
  ACE/angiotensin II/neprilysin inhibitors (%)            81.8                     90.9              NS
  ACE inhibitors (%)                                      36.4                     36.4              NS
  Angiotensin II inhibitors (%)                           27.3                     9.1               NS
  Neprilysin inhibitors (%)                               18.2                     36.4              NS
  Mineralocorticoid receptor antagonists (%)              81.8                     90.9              NS
  Furosemide dose (mg/day)                            80 \[40--80\]           40 \[40--80\]          NS

ACE, angiotensin‐converting enzyme; LVEF, left ventricular ejection fraction; METs, metabolic equivalents; MR, mitral regurgitation; NS, not significant; NT‐proBNP, N‐terminal pro‐brain natriuretic peptide; NYHA, New York Heart Association; OUES, oxygen uptake efficiency slope; RER, respiratory exchange ratio; SBP, systolic blood pressure; VAT, ventilatory anaerobic threshold; VE, ventilation; VO~2~, maximal peak oxygen consumption.

![Changes in VO~2~ before and after percutaneous mitral valve repair (PMVR).](EHF2-6-867-g002){#ehf212457-fig-0002}

![Changes in oxygen uptake efficiency slope (OUES) before and after percutaneous mitral valve repair (PMVR).](EHF2-6-867-g003){#ehf212457-fig-0003}

![Changes in ventilatory anaerobic threshold (VAT) before and after percutaneous mitral valve repair (PMVR).](EHF2-6-867-g004){#ehf212457-fig-0004}

Discussion {#ehf212457-sec-0008}
==========

Some reports have already highlighted the effectiveness of PMVR in patients with advanced HF candidates for heart transplantation or left ventricular assist device.[6](#ehf212457-bib-0006){ref-type="ref"}, [7](#ehf212457-bib-0007){ref-type="ref"} In our cohort, elective PMVR was related to an improved overall cardiopulmonary performance, including an increase in VO~2~ as the most robust prognostic parameter of CPET. Some aspects should be pointed out regarding these findings. First, interpretation of pre‐procedural and post‐procedural CPETs results might be challenging, especially in patients with advanced age and severe co‐morbidities.[3](#ehf212457-bib-0003){ref-type="ref"}, [8](#ehf212457-bib-0008){ref-type="ref"} Those patients were not included in this study. Second, FMR is a common finding among patients with HFrEF and has a negative impact on exercise capacity and clinical outcomes on standalone medical therapy.[9](#ehf212457-bib-0009){ref-type="ref"} Third, from a physiopathological perspective, PMVR reduces MR, thus decreasing left‐side volume overload and pulmonary pressures and increasing cardiac output.[10](#ehf212457-bib-0010){ref-type="ref"} And fourth, this haemodynamic enhancement has translated into positive left ventricular remodelling and improvement in clinical symptoms, quality of life, and 6 min walk test in different series.[11](#ehf212457-bib-0011){ref-type="ref"}, [12](#ehf212457-bib-0012){ref-type="ref"}, [13](#ehf212457-bib-0013){ref-type="ref"} Although only modest increments in LVEF have been reported in this scenario, these changes, alongside the reduction in regurgitant volume, imply an improvement in antegrade ejection flow that might be one of the underlying mechanisms for a better cardiopulmonary performance.[14](#ehf212457-bib-0014){ref-type="ref"} Given the good correlation reported between 6 min walk test and estimated VO~2~,[15](#ehf212457-bib-0015){ref-type="ref"} this result go alongside with prior findings. Because improvement in VO~2~ has always been considered a relevant prognostic factor in patients with HFrEF, our observation may explain some of the benefits of the MitraClip therapy. At this regard, to date, larger randomized controlled trial addressing prognosis impact of PMVR over medical therapy in patients with FMR showed a reduction in the need for advanced HF therapies, as well as an improved survival after clip implantation.[16](#ehf212457-bib-0016){ref-type="ref"} Conversely, the study of Obadia *et al*.[17](#ehf212457-bib-0017){ref-type="ref"} failed to show an improvement in prognosis after PMVR, which has been related to the inclusion of patients with very severely dilated left ventricular and less significant MR in this late study. Therefore, further trials are required to better discriminate best candidates for PMVR and determined if clinical improvement in patients with FMR translates in better survival outcomes and safe deference of advanced HF therapies.

Conclusions {#ehf212457-sec-0009}
-----------

In conclusion, although limited for the small number of patients included and the lack of a matched cohort, PMVR was related to an enhancement in cardiopulmonary performance in patients with systolic HF and no contraindication for advanced HF therapies in our series.
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